Furthermore, several groups refuted the application of GPI-derivative compounds as neurotrophic and neuroprotective agents for the treatment of Parkinson’s disease because these compounds bind poorly to FKBP12, opposing the earlier observations [276,277]. Here, FKBP1A is linked to Parkinson disease.